This clinical trial is for adults with HER2-negative breast cancer that has spread to the brain. **HER2-negative** means the cancer cells don’t have a protein that makes them grow faster. The trial tests a treatment combining two drugs: **utidelone** and **capecitabine**. Both drugs are studied for safety and effectiveness in treating brain cancer spots and the whole body. Participants must have at least one brain tumor that can be measured, confirmed through a special type of scan called an MRI (Magnetic Resonance Imaging). **Key Points:** - **Duration:** The study involves multiple visits; exact length depends on individual response to treatment. - **Participation:** Participants must be able to attend study visits and give written consent. - **Eligibility:** Individuals must meet specific health criteria, including adequate organ function and a life expectancy of at least 3 months. Before joining, individuals are screened to ensure they meet the study’s criteria. If you're considering participation, discuss potential benefits and risks with your doctor. Participants will need to avoid pregnancy during the study and for a time after.